Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: Critical role of duration of infection

Journal of the National Cancer Institute

Volumn 102, Issue 5, 2010, Pages 315-324

  Rodriguez, Ana Cecilia ^a,b   Schiffman, Mark ^b   Herrero, Rolando ^a   Hildesheim, Allan ^b   Bratti, Concepción ^a   Sherman, Mark E ^b   Solomon, Diane ^c   Guillén, Diego ^a   Alfaro, Mario ^a   Morales, Jorge ^a   Hutchinson, Martha ^d   Katki, Hormuzd ^b   Cheung, Li ^e   Wacholder, Sholom ^b   Burk, Robert D ^f  

^a PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^b Vaccine Safety Branch   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WOMEN AND INFANTS HOSPITAL   (United States)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; CYTOLOGY; DISEASE DURATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ADULT; AGE FACTORS; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; COSTA RICA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LONGITUDINAL STUDIES; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; YOUNG ADULT;

EID: 77749279734     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq001     Document Type: Article

References (42)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636.
2. Wright TC Jr., Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348(6):489-490.
3. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831-1836.
4. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5): 731-738.
5. Rodriguez AC, Burk R, Herrero R, et al. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis. 2007;34(7):494-502.
6. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-434.
7. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191(2):182-192.
8. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132(2):277-284.
9. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their frst sexual relationship. BJOG. 2002;109(1):96-98.
10. Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papil-lomavirus infection in a long-term follow-up study of female University students. J Infect Dis. 2008;198(7):971-978.
11. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100(7):513-517.
12. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specifc curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119(11):2677-2684.
13. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profle of type-specifc human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1796-1807. (Pubitemid 40705385)
14. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica. 1997;1(5):362-375. (Pubitemid 27428425)
15. Bratti MC, Rodriguez AC, Schiffman M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neo-plasia among 10000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica. 2004;15(2):75-89.
16. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1808-1816.
17. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158(5):486-494.
18. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5):1415-1423.
19. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190(12): 2077-2087.
20. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specifc human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169(2):235-240.
21. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283(1):87-93.
22. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol. 2002;68(3):417-423.
23. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classifcation of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527. (Pubitemid 36159887)
24. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204.
25. Gravitt PE, Kovacic MB, Herrero R, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer. 2007;121(12):2787-2793.
26. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens\part B: biological agents. Lancet Oncol. 2009;10(4):321-322
27. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA. 1989;262(7): 931-934.
28. Sherman ME, Schiffman M, Herrero R, et al. Performance of a semiau-tomated Papanicolaou smear screening system: results of a population-based study conducted in Guanacaste, Costa Rica. Cancer. 1998;84(5): 273-280.
29. Schneider DL, Herrero R, Bratti C, et al. Cervicography screening for cervical cancer among 8460 women in a high-risk population. Am J Obstet Gynecol. 1999;180(2, pt 1):290-298.
30. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007; 26(4):441-446.
31. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined signifcance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582-1589.
32. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types refects viral evolution. Virology. 2005;337(1):76-84.
33. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92(6):464-474.
34. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papilloma-virus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-753.
35. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428.
36. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66(21):10630-10636.
37. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specifc HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
38. Goodman MT, Shvetsov YB, McDuffe K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res. 2008;68(21):8813-8824.
39. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papilloma-virus infection. N Engl J Med. 1992;327(18):1272-1278.
40. Castle PE, Rodriguez AC, Burk RD, et al. Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer. 2009;125(7):1649-1656.
41. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillo-mavirus and risk of CIN3 or cervical cancer. Lancet. 2002;360(9328): 228-229.
42. Hesselink AT, Berkhof J, Heideman DA, et al. High-risk human papillo-mavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int J Cancer. 2009;124(2):381-386.